Clinical trials: Activities, Motor
Advanced Hip Disease
Durom(R) Hip Resurfacing System Multicenter Trial
The purpose of the study is to gather clinical information on the safety and efficacy of the resurfacing devices in the young, active patient with advanced hip disease.
- Trial name
- NCT00746616
- Testing
- Durom Hip Resurfacing System
- Where
- 5 sites in United States
- Volunteers
- 40 people
- Sponsor
- Zimmer Biomet
Schizophrenia
A Randomized, Open-Label, Multi-Center Study To Evaluate The Efficacy And Safety Of Intramuscular Ziprasidone In Patients With Agitation
This local registration study is to confirm the hypothesis of the efficacy, tolerability and safety of ziprasidone IM (intramuscular) in the Chinese population with agitation in schizophrenia
- Trial name
- NCT00723606
- Testing
- Intramuscular ziprasidone mesylate, Intramuscular haloperidol
- Where
- 9 sites in China
- Volunteers
- 376 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ulcerative Colitis
A Phase III Trial of HMPL-004 in Patients With Mild to Moderate Active Ulcerative Colitis
A placebo controlled study of two doses of HMPL-004 in patients with active mild to moderate ulcerative colitis (UC), with a modified Mayo Score 4-10 and an endoscopy subscore of 2-3, taking mesalamine (or equivalent) as a…
- Trial name
- NCT01805791
- Testing
- HMPL-004 1800 mg/day, HMPL-004 2400 mg/day
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Hutchison Medipharma Limited
Agitation, Delirium
Study of BXCL501 In Agitation Associated With Delirium in ICU Patients
This study is designed to determine and evaluate the optimal BXCL501 starting dose (StartD) that will safely and effectively reduce agitation associated with delirium in ICU patients.
- Trial name
- NCT05313386
- Testing
- BXCL501
- Where
- United States
- Sponsor
- BioXcel Therapeutics Inc
Symptomatic, Aggressive, Sporadic, Unresectable, Locally, Advanced/Metastatic Medullary Thyroid Cancer (MTC)
Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer
This is a European multinational, multicenter, non-interventional (observational) and prospective study. It is carried on to confirm in real life conditions the benefit/risk of vandetanib (CAPRELSA™) 300 mg, both in RET negative…
- Trial name
- Caprelsa104 (NCT01945762)
- Testing
- Vandetanib 300 mg
- Where
- 8 sites in Belgium, France and 6 more
- Volunteers
- 31 people
- Sponsor
- Genzyme, a Sanofi Company
Alzheimer Disease
Memesto Wearable Device for Persons With Dementia
An estimated 70% of the 7.2+ million people in the U.S. with Alzheimer's Disease and Alzheimer's Disease-Related Dementias experience agitation, characterized by poorly organized and purposeless psychomotor activity that…
- Trial name
- NCT05153161
- Testing
- Memesto
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Edgewater Safety Systems, Inc.
Obesity
Study to Explore the Safety and Efficacy of NT-0796 as an Adjunct to Semaglutide in Participants With Obesity (RESOLVE-2)
A Phase 2a randomized, double-blind, placebo-controlled, parallel-group, multicenter study to explore the safety and efficacy of NT-0796 as an adjunct to semaglutide in participants with obesity over a 6 months treatment period.
- Trial name
- RESOLVE-2 (NCT07220629)
- Testing
- NT-0796
- Where
- 9 sites in United States
- Volunteers
- 82 people
- Sponsor
- Rezera (formerly NodThera Limited)
Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease
A Study to Assess the Long-term Safety and Efficacy of AXS-05 in Subjects With Alzheimer's Disease Agitation
This study will evaluate the long-term safety and efficacy of AXS-05 in subjects with Alzheimer's disease (AD) agitation.
- Conditions
- Agitation in Patients With Dementia of the Alzheimer's Type, Alzheimer Disease, Agitation, Psychomotor
- Trial name
- ACCORD-2 (NCT04947553)
- Testing
- AXS-05 (dextromethorphan-bupropion)
- Where
- 47 sites in United States, Canada and 1 more
- Volunteers
- 456 people
- Sponsor
- Axsome Therapeutics, Inc.
Colitis, Ulcerative
A Study of Safety and Effectiveness of JNJ-54781532 in Patients With Moderately to Severely Active Ulcerative Colitis
The purpose of the study is to evaluate dose response of JNJ-54781532 in participants with moderately to severely active ulcerative colitis (UC).
- Trial name
- NCT01959282
- Testing
- JNJ-54781532 25 mg once daily, JNJ-54781532 75 mg once daily, JNJ-54781532 150 mg once daily
- Where
- 97 sites in United States, Australia and 12 more
- Volunteers
- 219 people
- Sponsor
- Janssen Research & Development, LLC
Dehydration
Dehydration, Rehydration, and Blood Viscosity
The purpose of this study is to examine and compare the rehydration effect of Essentia Water, an electrolyzed high-pH bottled water, with industry-standard bottled water purified by reverse osmosis with minerals added, on (1)…
- Trial name
- NCT02118883
- Testing
- Essentia Water, Bottled water
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Essentia Water, LLC
Obesity, Morbid, Bariatric Surgery Candidate
Health-connected Devices and Physical Activity Recovery in Bariatric Surgery Patients
The goal of clinical trial is to evaluate the impact of use of health-connected devices and of an Internet-based Intensive follow-up on physical activity recovery during the 6-month period after bariatric surgery in obese…
- Trial name
- MYGOODTRIP (NCT02716480)
- Testing
- Mobility coaching, Diet coaching
- Where
- France
- Volunteers
- 90 people
- Sponsor
- My Goodlife SAS
Agitation,Psychomotor, Dementia
Sub-Lingual Dexmedetomidine in Agitation Associated With Dementia
This is an adaptive Phase 1b/2 trial design. It is randomized, double-blind, placebo-controlled, multiple ascending dose study assessing efficacy, pharmacokinetics, safety and tolerability of BXCL-501 dosing in adult (65 years…
- Trial name
- TRANQUILITY (NCT04251910)
- Testing
- Sublingual film containing Dexmedetomidine
- Where
- 5 sites in United States
- Volunteers
- 100 people
- Sponsor
- BioXcel Therapeutics Inc
Nervousness, Restlessness
Effectiveness of NEURAPAS Balance in Children With Nervous Restlessness
Purpose: To document data on effectiveness of NEURAPAS® balance (NPB) in the treatment of nervous restlessness in children aged 6 to 12. Each patient is treated with NPB. No placebo group is established.
- Conditions
- Nervousness, Restlessness, Depression (Agitated), Affective Disorders
- Trial name
- NCT01125579
- Where
- Germany
- Volunteers
- 115 people
- Sponsor
- Pascoe Pharmazeutische Praeparate GmbH
Bronchospasm, Activity/Exercise Induced Bronchospasm
A Study Measuring Asthma Control In Pediatric And Adolescent Subjects Whose Asthma Is Worsened By Activity Or Exercise
During this study, your child will need to attend up to 5 office visits and maintain regular telephone contact with the clinic. Certain office visits will include physical exams, medical history review, exercise challenge test…
- Trial name
- NCT00118690
- Testing
- Fluticasone propionate/salmeterol
- Where
- 51 sites in United States
- Volunteers
- 227 people
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis
Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS)
This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early efficacy of Q-Cells® transplantation in subjects…
- Trial name
- NCT02478450
- Testing
- Q-Cells
- Volunteers
- 30 people
- Sponsor
- Q Therapeutics, Inc.
COPD
Study to Evaluate the Impact of the "PROactive Telecoaching Program" on Physical Activity in Patients With COPD.
This study will test two instruments to measure physical activity in COPD patients: A questionnaire and two small physical activity monitors .Patients will be randomized to either receive the telecoaching program in addition to…
- Trial name
- PROactive (NCT01992081)
- Testing
- Automated telehealth system, Usual care
- Sponsor
- Novartis Pharmaceuticals
Neoplasms, Solid Tumors
ADC-1013 First-in-Human Study
The purpose of this study is to determine whether ADC-1013 (an agonistic human monoclonal IgG1 anti-CD40 antibody) is safe and tolerable when administered intratumorally (as repeated injections directly into the tumor tissue) or…
- Trial name
- NCT02379741
- Testing
- ADC-1013
- Where
- 5 sites in Denmark, Sweden and 1 more
- Volunteers
- 24 people
- Sponsor
- Alligator Bioscience AB
Neurobehavioral Disinhibition
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury
This is a multicenter, randomized, placebo-controlled study to evaluate AVP-786 for the treatment of neurobehavioral disinhibition including aggression, agitation, and irritability in participants with traumatic brain injury…
- Trial name
- NCT03095066
- Testing
- AVP-786-28, AVP-786-42.63
- Where
- 54 sites in United States
- Volunteers
- 168 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Rheumatoid Arthritis
A Study Exploring the Safety, Tolerability, and Efficacy of a 28 Day Course Followed by an Additional 56 Day Course of Itacitinib in Subjects With Active Rheumatoid Arthritis
This is a study evaluating a 28-day course followed by a 56-day course of itacitinib in patients with active rheumatoid arthritis (RA). The study will evaluate safety and efficacy parameters of itacitinib.
- Trial name
- NCT01626573
- Testing
- Itacitinib
- Where
- 18 sites in United States, Puerto Rico
- Volunteers
- 106 people
- Sponsor
- Incyte Corporation
Hemophilia A
Study to Learn More About the Physical Activity Level of Patients Suffering From Hemophilia A Treated With Damoctocog Alfa Pegol (LIFE ACTIVE Study)
In this study researcher want to learn more about the change of physical activity of hemophilia A patients treated with damoctocog alfa pegol.
- Trial name
- LIFE-ACTIVE (NCT04091386)
- Testing
- Damoctocog alfa pegol (Jivi, BAY94-9027)
- Where
- 8 sites in United States, Belgium and 5 more
- Volunteers
- 10 people
- Sponsor
- Bayer